pilocarpine has been researched along with Injuries, Radiation in 36 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total number of 60 patients were randomized into the trial, but unfortunately only 39 patients were finally evaluated for xerostomia, 18 in the pilocarpine and 21 in the placebo group." | 9.10 | A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. ( Haddad, P; Karimi, M, 2002) |
| "No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands: (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters: (3) all responders are identified at 12 weeks." | 9.09 | Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. ( Alfonsi, M; Ardiet, JM; Baillet, F; Bensadoun, RJ; Bolla, M; Bourdin, S; Calais, G; Coche-Dequéant, B; Coscas, Y; Desprez, P; Horiot, JC; Lapeyre, M; Lipinski, F; Maral, J; Maulard-Durdux, C; Montbarbon, X; Pene, F; Schraub, S; Urbajtel, M; Vinke, J; Wibault, M, 2000) |
| "Eighteen patients with xerostomia refractory to pilocarpine therapy after XRT for head and neck malignancy were offered acupuncture as palliation." | 9.09 | Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. ( Inouye, WS; Johnstone, PA; May, BC; Niemtzow, RC; Peng, YP, 2001) |
| "Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month multicenter maintenance study to evaluate the long-term safety and efficacy of oral pilocarpine for the treatment of radiation-induced xerostomia." | 9.08 | A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. ( Jacobs, CD; van der Pas, M, 1996) |
| "Pilocarpine has some efficacy in the treatment of xerostomia from radiation therapy, graft-versus-host disease and Sjögren's syndrome." | 8.84 | Systemic pilocarpine for treatment of xerostomia. ( Berk, L, 2008) |
| "This article examines the use of pilocarpine hydrochloride for radiation-induced xerostomia in patients with head and neck cancer." | 8.80 | Pilocarpine for radiation-induced xerostomia in head and neck cancer. ( Hawthorne, M; Sullivan, K, 2000) |
| "To analyze the role of oral pilocarpine in the treatment of xerostomia of Sjogren's syndrome (SS)." | 8.80 | The use of oral pilocarpine in xerostomia and Sjögren's syndrome. ( Nusair, S; Rubinow, A, 1999) |
| "Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal whole saliva production ≥0." | 6.77 | Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. ( Berk, L; Cardinale, F; James, JL; Lukaszczyk, B; Nguyen-Tân, PF; Sagar, S; Singh, AK; Wong, RK; Wyatt, G; Yeh, AM, 2012) |
| "To investigate the effect of concomitant administration of pilocarpine during radiotherapy for head-and-neck squamous cell carcinoma (HNSCC) on postradiotherapy xerostomia." | 5.13 | Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. ( Burlage, FR; Coppes, RP; Kampinga, HH; Langendijk, JA; Roesink, JM; Stokman, MA; Terhaard, C; van Luijk, P; Vissink, A, 2008) |
| "The efficacy of pilocarpine given during radiotherapy for head-neck cancer to reduce xerostomia was assessed." | 5.11 | Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. ( Black, M; Gornitsky, M; Hier, M; Katz, H; Shenouda, G; Sultanem, K; Velly, AM, 2004) |
| "A total number of 60 patients were randomized into the trial, but unfortunately only 39 patients were finally evaluated for xerostomia, 18 in the pilocarpine and 21 in the placebo group." | 5.10 | A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. ( Haddad, P; Karimi, M, 2002) |
| "No difference was found according to dose/volume radiotherapy parameters suggesting that oral pilocarpine hydrochloride: (1) acts primarily by stimulating minor salivary glands: (2) can be of benefit to patients suffering of severe xerostomia regardless of radiotherapy dose/volume parameters: (3) all responders are identified at 12 weeks." | 5.09 | Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. ( Alfonsi, M; Ardiet, JM; Baillet, F; Bensadoun, RJ; Bolla, M; Bourdin, S; Calais, G; Coche-Dequéant, B; Coscas, Y; Desprez, P; Horiot, JC; Lapeyre, M; Lipinski, F; Maral, J; Maulard-Durdux, C; Montbarbon, X; Pene, F; Schraub, S; Urbajtel, M; Vinke, J; Wibault, M, 2000) |
| "Eighteen patients with xerostomia refractory to pilocarpine therapy after XRT for head and neck malignancy were offered acupuncture as palliation." | 5.09 | Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. ( Inouye, WS; Johnstone, PA; May, BC; Niemtzow, RC; Peng, YP, 2001) |
| "Two hundred sixty-five patients with head and neck cancer who had previously participated in either a fixed-dose, dose-titration, or dose-ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36-month multicenter maintenance study to evaluate the long-term safety and efficacy of oral pilocarpine for the treatment of radiation-induced xerostomia." | 5.08 | A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. ( Jacobs, CD; van der Pas, M, 1996) |
| "There is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced xerostomia." | 4.91 | Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. ( Davies, AN; Thompson, J, 2015) |
| "Pilocarpine has some efficacy in the treatment of xerostomia from radiation therapy, graft-versus-host disease and Sjögren's syndrome." | 4.84 | Systemic pilocarpine for treatment of xerostomia. ( Berk, L, 2008) |
| "This article examines the use of pilocarpine hydrochloride for radiation-induced xerostomia in patients with head and neck cancer." | 4.80 | Pilocarpine for radiation-induced xerostomia in head and neck cancer. ( Hawthorne, M; Sullivan, K, 2000) |
| "To analyze the role of oral pilocarpine in the treatment of xerostomia of Sjogren's syndrome (SS)." | 4.80 | The use of oral pilocarpine in xerostomia and Sjögren's syndrome. ( Nusair, S; Rubinow, A, 1999) |
| "Patients with cancer of the head and neck who were 3 to 24 months from completing radiotherapy with or without chemotherapy (RT ± C) and who were experiencing xerostomia symptoms with basal whole saliva production ≥0." | 2.77 | Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia. ( Berk, L; Cardinale, F; James, JL; Lukaszczyk, B; Nguyen-Tân, PF; Sagar, S; Singh, AK; Wong, RK; Wyatt, G; Yeh, AM, 2012) |
| "Pilocarpine has been approved for post-radiation xerostomia, and the effect of its use during radiation therapy on salivary flow, xerostomia, mucositis, and quality of life (QOL) was assessed in a phase III study conducted by the Radiation Therapy Oncology Group (RTOG 97-09)." | 2.72 | Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. ( Brachman, D; Foote, R; Hodson, DI; Lee, N; LeVeque, F; Meredith, R; Scarantino, C; Schulsinger, A; Swann, RS; White, R, 2006) |
| "Patients with head and neck cancers can develop salivary hypofunction after radiotherapy." | 2.70 | Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours. ( Ferre, J; Fuster, D; Lomeña, F; Martin, F; Mateos, JJ; Navalpotro, B; Ortega, M; Pavia, J; Pons, F; Rovirosa, A; Setoain, X, 2001) |
| "Radiation induced xerostomia is a frequent consequence of radiotherapy (RT) for head-neck cancer (HNC) patients, when parotid glands are included in the radiation fields." | 2.43 | Preventing radiation induced xerostomia. ( Danielidis, V; Koukourakis, MI, 2005) |
| "Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients." | 2.43 | Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006) |
| "Head and neck cancer is becoming a more recognizable pathology to the general population and dentists." | 2.43 | Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia. ( Chai, WL; Ngeow, WC; Rahman, RA; Ramli, R, 2006) |
| "Xerostomia is one of the most common side effects of head and neck radiation therapy." | 2.40 | Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy. ( Garg, AK; Malo, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.56) | 18.7374 |
| 1990's | 8 (22.22) | 18.2507 |
| 2000's | 21 (58.33) | 29.6817 |
| 2010's | 4 (11.11) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, XY | 1 |
| Liu, KJ | 1 |
| Zhang, FY | 1 |
| Xiang, B | 1 |
| Malallah, OS | 1 |
| Garcia, CMA | 1 |
| Proctor, GB | 1 |
| Forbes, B | 1 |
| Royall, PG | 1 |
| López-López, J | 1 |
| Jané Salas, E | 1 |
| Chimenos Küstner, E | 1 |
| Davies, AN | 2 |
| Thompson, J | 1 |
| Berk, L | 2 |
| Wong, RK | 1 |
| James, JL | 1 |
| Sagar, S | 1 |
| Wyatt, G | 1 |
| Nguyen-Tân, PF | 1 |
| Singh, AK | 1 |
| Lukaszczyk, B | 1 |
| Cardinale, F | 1 |
| Yeh, AM | 1 |
| Haddad, P | 1 |
| Karimi, M | 1 |
| Hawthorne, M | 1 |
| Sullivan, K | 1 |
| Taylor, SE | 2 |
| DANYSZ, A | 1 |
| PRONIEWSKI, H | 1 |
| WISNIEWSKI, K | 1 |
| ZACZEK, T | 1 |
| POLOCKI, B | 1 |
| SETAELAE, K | 1 |
| LINDROOS, B | 1 |
| KUIKKA, AO | 1 |
| Gornitsky, M | 1 |
| Shenouda, G | 1 |
| Sultanem, K | 1 |
| Katz, H | 1 |
| Hier, M | 1 |
| Black, M | 1 |
| Velly, AM | 1 |
| Aframian, DJ | 1 |
| Palmon, A | 1 |
| Nahlieli, O | 1 |
| Ramos, FM | 1 |
| Pontual, ML | 1 |
| de Almeida, SM | 1 |
| Bóscolo, FN | 1 |
| Tabchoury, CP | 1 |
| Novaes, PD | 1 |
| Koukourakis, MI | 1 |
| Danielidis, V | 1 |
| de Castro, G | 1 |
| Federico, MH | 1 |
| Scarantino, C | 1 |
| LeVeque, F | 1 |
| Swann, RS | 1 |
| White, R | 1 |
| Schulsinger, A | 1 |
| Hodson, DI | 1 |
| Meredith, R | 1 |
| Foote, R | 1 |
| Brachman, D | 1 |
| Lee, N | 1 |
| Ngeow, WC | 1 |
| Chai, WL | 1 |
| Rahman, RA | 1 |
| Ramli, R | 1 |
| Shiboski, CH | 1 |
| Hodgson, TA | 1 |
| Ship, JA | 1 |
| Schiødt, M | 1 |
| Shorthose, K | 1 |
| Burlage, FR | 1 |
| Roesink, JM | 1 |
| Kampinga, HH | 3 |
| Coppes, RP | 3 |
| Terhaard, C | 1 |
| Langendijk, JA | 1 |
| van Luijk, P | 1 |
| Stokman, MA | 1 |
| Vissink, A | 1 |
| Jacobs, CD | 1 |
| van der Pas, M | 1 |
| Kumar, S | 1 |
| Tyler, AB | 1 |
| Phillips, S | 1 |
| Burnet, NG | 1 |
| Garg, AK | 1 |
| Malo, M | 1 |
| Tishler, M | 1 |
| Miller, EG | 1 |
| Nusair, S | 1 |
| Rubinow, A | 1 |
| Horiot, JC | 1 |
| Lipinski, F | 1 |
| Schraub, S | 1 |
| Maulard-Durdux, C | 1 |
| Bensadoun, RJ | 1 |
| Ardiet, JM | 1 |
| Bolla, M | 1 |
| Coscas, Y | 1 |
| Baillet, F | 1 |
| Coche-Dequéant, B | 1 |
| Urbajtel, M | 1 |
| Montbarbon, X | 1 |
| Bourdin, S | 1 |
| Wibault, M | 1 |
| Alfonsi, M | 1 |
| Calais, G | 1 |
| Desprez, P | 1 |
| Pene, F | 1 |
| Lapeyre, M | 1 |
| Vinke, J | 1 |
| Maral, J | 1 |
| Johnstone, PA | 1 |
| Peng, YP | 1 |
| May, BC | 1 |
| Inouye, WS | 1 |
| Niemtzow, RC | 1 |
| Mateos, JJ | 1 |
| Setoain, X | 1 |
| Ferre, J | 1 |
| Rovirosa, A | 1 |
| Navalpotro, B | 1 |
| Martin, F | 1 |
| Ortega, M | 1 |
| Lomeña, F | 1 |
| Fuster, D | 1 |
| Pavia, J | 1 |
| Pons, F | 1 |
| Zeilstra, LJ | 1 |
| Konings, AW | 1 |
| O'Connell, AC | 1 |
| Licht, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| Effect of Pilocarpine in Patients With Xerostomia[NCT02982577] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Finger-prick Autologous Blood (FAB) for Use in Dry Mouth[NCT03530735] | 20 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | |||
| A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia[NCT00656513] | Phase 2/Phase 3 | 196 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated With Curative Radiation Therapy in Head and Neck Cancer Patients[NCT00003139] | Phase 3 | 249 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This secondary objective was to evaluate the effect of ALTENS treatment on overall radiation-induced xerostomia burden by looking at treatment response. Treatment response was determined by a reduction of at least 20% from baseline to 6 months in the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4. Higher scores indicate increased xerostomia burden. This scale has high reproducibility and sensitivity. For the first and second stage analyses, 4 and 10 patients, respectively, must respond to treatment in order to proceed to the phase III component. (NCT00656513)
Timeframe: Pre-treatment and 6 months from registration
| Intervention | percentage of participants (Number) |
|---|---|
| ALTENS: Phase II | 85.7 |
Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden. (NCT00656513)
Timeframe: Baseline (randomization) and 9 months
| Intervention | units on a scale (Median) |
|---|---|
| Pilocarpine: Phase III | -0.27 |
| ALTENS: Phase III | -0.53 |
The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement. (NCT00656513)
Timeframe: Baseline and 9 months from randomization.
| Intervention | units on a scale (Median) |
|---|---|
| Pilocarpine: Phase III | -3.64 |
| ALTENS: Phase III | -7.27 |
Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden. (NCT00656513)
Timeframe: Baseline, 4, 6, and 15 months from randomization
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| 4 months | 6 months | 15 months | |
| ALTENS: Phase III | -0.47 | -0.4 | -0.6 |
| Pilocarpine: Phase III | -0.27 | -0.33 | -0.47 |
Stimulated (citric acid primed) whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. Stimulation is elicited by asking patients to rinse 5 ml of 2% citric acid solution in the mouth for 15 seconds and then completely expectorating the citric acid. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected. (NCT00656513)
Timeframe: Baseline, 4, 6, 9 and 15 months from randomization
| Intervention | ml/min (Median) | |||
|---|---|---|---|---|
| 4 months | 6 months | 9 months | 15 months | |
| ALTENS: Phase III | 0.2 | 0.40 | 0.60 | 0.20 |
| Pilocarpine: Phase III | 0.03 | 0.2 | 0.99 | 0.3 |
Symptom burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning. The domain score is the average of all responses on a given domain and can range from 0 to 4, with higher scores indicating increased symptom burden. Change in symptom burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the symptom burden. (NCT00656513)
Timeframe: Baseline, 4, 6, 9 and 15 months from randomization
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4-month Physical Functioning | 4-month Pain/Discomfort | 4-month Personal/Psychological Functioning | 4-month Social Functioning | 6-month Physical Functioning | 6-month Pain/Discomfort | 6-month Personal/Psychological Functioning | 6-month Social Functioning | 9-month Physical Functioning | 9-month Pain/Discomfort | 9-month Personal/Psychological Functioning | 9-month Social Functioning | 15-month Physical Functioning | 15-month Pain/Discomfort | 15-month Personal/Psychological Functioning | 15-month Social Functioning | |
| ALTENS: Phase III | -0.5 | -0.375 | -0.5 | -0.33 | -0.5 | -0.5 | -0.5 | -0.33 | -0.5 | -0.5 | -0.75 | -0.33 | -0.75 | -0.5 | -0.75 | -0.33 |
| Pilocarpine: Phase III | -0.5 | -0.25 | -0.25 | 0 | -0.5 | -0.25 | -0.25 | -0.33 | -0.5 | -0.25 | -0.5 | -0.66 | -0.5 | -0.5 | -0.5 | 0 |
Basal whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected. (NCT00656513)
Timeframe: Pre-treatment to 4, 6, 9 and 15 months from randomization
| Intervention | ml/min (Median) | |||
|---|---|---|---|---|
| 4 months | 6 months | 9 months | 15 months | |
| ALTENS: Phase III | 0 | 0.02 | 0.04 | 0.192 |
| Pilocarpine: Phase III | 0 | 0 | 0.056 | 0.13 |
Patients completing at least 19 out of 24 ALTENS therapy sessions were categorized as compliant. Fleming's two-stage was used, assuming a successful target compliance rate of 80%, statistical power of 0.87, and a type I error rate of 0.13. If fewer than 9 of the first 13 patients were compliant, then treatment delivery will be deemed not feasible. If there were between 9-12 compliant patients, the second stage analysis would be required to determine feasibility of treatment delivery. If all 13 patients are compliant, treatment delivery will immediately be deemed feasible. The second stage analysis required at least 31 compliant out of 39 overall patients for the treatment delivery to be deemed feasible. (NCT00656513)
Timeframe: Randomization to 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| First Stage | Second Stage (Overall) | |
| ALTENS: Phase II | 12 | 44 |
16 reviews available for pilocarpine and Injuries, Radiation
| Article | Year |
|---|---|
Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
Topics: Drug Delivery Systems; Head and Neck Neoplasms; Humans; Mouth Mucosa; Muscarinic Agonists; Pilocarpi | 2018 |
[Prognosis and treatment of dry mouth. Systematic review].
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Dental Caries; Disease Susceptibility; Double-Bli | 2014 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2015 |
Systemic pilocarpine for treatment of xerostomia.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation I | 2008 |
Pilocarpine for radiation-induced xerostomia in head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Randomized Co | 2000 |
Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia.
Topics: Antifungal Agents; Cost-Benefit Analysis; Fluorides; Head and Neck Neoplasms; Humans; Muscarinic Ago | 2003 |
Preventing radiation induced xerostomia.
Topics: Head and Neck Neoplasms; Humans; Incidence; Muscarinic Agonists; Pilocarpine; Quality of Life; Radia | 2005 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S | 2006 |
Managing complications of radiation therapy in head and neck cancer patients: Part I. Management of xerostomia.
Topics: Chewing Gum; Head and Neck Neoplasms; Humans; Mouthwashes; Parasympatholytics; Pilocarpine; Radiatio | 2006 |
Management of salivary hypofunction during and after radiotherapy.
Topics: Amifostine; Dental Caries; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation-P | 2007 |
Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy.
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Randomized Contr | 2007 |
Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy.
Topics: Cariostatic Agents; Chronic Disease; Dental Caries; Fluorides; Gels; Head and Neck Neoplasms; Humans | 1997 |
[Pilocarpine--new use for an old drug].
Topics: Humans; Muscarinic Agonists; Parasympathomimetics; Pilocarpine; Radiation Injuries; Radiotherapy; Xe | 1998 |
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease; | 1999 |
The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
Topics: Administration, Oral; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; Radiation I | 1999 |
Natural history and prevention of radiation injury.
Topics: Animals; Disease Models, Animal; Disease Progression; Free Radical Scavengers; Humans; Muscarinic Ag | 2000 |
9 trials available for pilocarpine and Injuries, Radiation
| Article | Year |
|---|---|
Phase 2 results from Radiation Therapy Oncology Group Study 0537: a phase 2/3 study comparing acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating early radiation-induced xerostomia.
Topics: Acupuncture; Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Male; Middle A | 2012 |
A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Drug Administration Schedule; He | 2002 |
Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer.
Topics: Analysis of Variance; Cranial Irradiation; Double-Blind Method; Female; Head and Neck Neoplasms; Hum | 2004 |
Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
Topics: Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Muscarinic Agonists; Pilocarpine; Qualit | 2006 |
Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Double-Blind Method; Female; Head and Neck Neopla | 2008 |
A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia.
Topics: Administration, Oral; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 1996 |
Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Head and Neck Neoplasms; Humans; Male; | 2000 |
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies.
Topics: Acupuncture Therapy; Drug Resistance; Head and Neck Neoplasms; Humans; Miotics; Pilocarpine; Radiati | 2001 |
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Mi | 2001 |
11 other studies available for pilocarpine and Injuries, Radiation
| Article | Year |
|---|---|
Nicotinamide mitigates radiation injury in submandibular gland by protecting mitochondrial structure and functions.
Topics: Adenosine Triphosphate; Animals; DNA Nucleotidylexotransferase; Humans; Mitochondria; NAD; Niacinami | 2022 |
REACTIVITY TO VEGETATIVE DRUGS IN THE ACUTE RADIATION SICKNESS.
Topics: Acetylcholine; Atropine; Cats; Dogs; Epinephrine; Guinea Pigs; Iproniazid; Mice; Neostigmine; Nicoti | 1963 |
[ON THE REMOVAL OF INCORPORATED STRONTIUM ISOTOPES IN EXPERIMENTAL ANIMALS. THEORETICAL PRINCIPLES FOR THE DECORPORATION TECHNIC WITH SOME EXPERIMENTAL RESULTS].
Topics: Animals; Bone and Bones; Cats; Mice; Pharmacology; Pilocarpine; Radiation Injuries; Radiation Injuri | 1964 |
[Future therapy strategies for salivary gland impairment].
Topics: Amifostine; Cranial Irradiation; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; | 2004 |
Evaluation of radioprotective effect of vitamin E in salivary dysfunction in irradiated rats.
Topics: Animals; Gamma Rays; Male; Pilocarpine; Radiation Injuries; Radiation-Protective Agents; Rats; Rats, | 2006 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi | 2006 |
Oral pilocarpine for xerostomia.
Topics: Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Pilocarpine; Radiation Injuries; Radiothe | 1994 |
Severity of xerostomia reduced when Salagen tablets taken during radiation therapy.
Topics: Drug Administration Schedule; Head and Neck Neoplasms; Humans; Pilocarpine; Radiation Injuries; Sali | 1996 |
Oral pilocarpine improves radiotherapy-induced dry eyes.
Topics: Aged; Eye; Eye Diseases; Hemangiosarcoma; Humans; Keratitis; Male; Parasympathomimetics; Pilocarpine | 1997 |
Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Head and Neck Neoplasms; Isoproterenol | 2001 |
Salivary gland-sparing prophylactic pilocarpine treatment has no effect on tumor regrowth after irradiation.
Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Dose-Response Relationship, Radiation; Humans; Mic | 2002 |